The Captial Market (CapitalMarket.com) rating for Concord Biotech IPO is 44. Their analysis recommends Avoid, However active risk seekers can try for the IPO.

Reviewer	Rating Score	Rating
Capital Market	44	Avoid, However active risk seekers can try

Concord Biotech IPO Review by Dilip Davda May apply

[Dilip Davda] The company is an Indian biopharma company with many niche products. It marked a setback in the bottom line for FY22 but posted growth in the top line for the reported three fiscals. Based on FY23 financial performance, the issue appears fully priced. This entire issue is by way of OFS and no fund is going to the company. Well-informed investors may park funds for the medium to long-term rewards. Read detail review...

Concord Biotech IPO Review by Members

Concord Biotech IPO Reviews, analysis and views by popular members. Read Concord Biotech Ltd. IPO reviews by retail investors to find recommended ipo to buy.

Concord Biotech IPO Review Summary by Members

Review By	Apply	May Apply	Neutral	Avoid
Count	0	0	0	0
%	0.00	0.00	0.00	0.00

Member	Review
No recommendation found. Be the first to post the recommendation.

Manage Recommendations

Note:

The recommendations or analysis of public issues posted above expresses the views of its author and does not represent the views of Chittorgarh.com or its staff.
We reserve the right to remove any objectionable post without providing a reason.

Concord Biotech IPO Review & Recommendations

Concord Biotech IPO Review Summary from brokers and analysts

Concord Biotech IPO Capital Market Rating

Concord Biotech IPO Review by Dilip Davda May apply

Concord Biotech IPO Review by Members

Concord Biotech IPO Review Summary by Members

Read more about Concord Biotech IPO